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Intramembrane proteolysis governs many cellular
control processes, but little is known about how in-
tramembrane proteases are regulated. iRhoms are
a conserved subfamily of proteins related to rhom-
boid intramembrane serine proteases that lack
key catalytic residues. We have used a combination
of genetics and cell biology to determine that
these ‘‘pseudoproteases’’ inhibit rhomboid-depen-
dent signaling by the epidermal growth factor
receptor pathway in Drosophila, thereby regulating
sleep. iRhoms prevent the cleavage of potential
rhomboid substrates by promoting their destabiliza-
tion by endoplasmic reticulum (ER)-associated
degradation; this mechanism has been conserved
in mammalian cells. The exploitation of the intrinsic
quality control machinery of the ER represents
a new mode of regulation of intercellular signaling.
Inactive cognates of enzymes are common, but their
functions are mostly unclear; our data indicate that
pseudoenzymes can readily evolve into regulatory
proteins, suggesting that this may be a significant
evolutionary mechanism.
INTRODUCTION
Intramembrane proteases are widespread and control important
cellular processes, but many questions remain about their func-
tion and regulation. There are four known families: presenilins/
gamma secretase, implicated in Alzheimer’s disease and Notch
signaling (Haass and De Strooper, 1999); site-2 protease, first
discovered as a regulator of cholesterol biosynthesis (Brown
and Goldstein, 1997; Makinoshima and Glickman, 2006); signal
peptide peptidase (Weihofen et al., 2002); and the most recently
discovered, rhomboids (Urban et al., 2001). Rhomboids are
serine proteases, conserved across all kingdoms of life, and
they regulate processes as diverse as growth factor signaling,
mitochondrial morphology, parasitic invasion, and bacterial
protein translocation (Freeman, 2008; Urban, 2009). Extensive
cell biology, biochemistry, and structural determination have
provided insights into rhomboid mechanism, although, as withthe other intramembrane proteases, much less is known about
how rhomboid-dependent processes are regulated. This is
a key question, as proteolysis is irreversible and often has potent
cellular consequences.
Phylogenetic analysis of rhomboids identified a subgroup of
rhomboid-like proteins that lack essential catalytic residues
(Lemberg and Freeman, 2007). These ‘‘iRhoms’’ (for inactive
rhomboids [Lemberg and Freeman, 2007]) are mysterious
because, despite their predicted lack of protease activity, they
are present in all sequenced metazoans, and their high degree
of sequence identity implies selective pressure. Little is known
about their function, but human iRhom1/Rhbdf1 has been
reported to be necessary for the survival of some epithelial
cancer cells (Yan et al., 2008) and may be linked to GPCR-medi-
ated EGFR transactivation (Zou et al., 2009).
iRhoms exemplify a more general phenomenon: the existence
of conserved but catalytically inactive cognates of enzymes. The
widespread occurrence of this type of predicted protein has
only been apparent since genome sequences have been avail-
able (Pils and Schultz, 2004; Bartlett et al., 2003), and their
function is largely unknown. They are not generally encoded by
pseudogenes and are therefore presumed to be expressed.
Bioinformatic analysis has led to the suggestion that inactive
enzyme cognates are disproportionately involved in regulatory
processes (Pils and Schultz, 2004).
In Drosophila, active rhomboids are cardinal regulators of
epidermal growth factor receptor (EGFR) signaling (Urban
et al., 2001), and although it is unclear whether this activity is
conserved in mammals (Blobel et al., 2009), recent evidence
supports some evolutionary conservation (Adrain et al., 2011).
Until now, nothing has been reported about iRhom function in
Drosophila. We have used a combination of genetics and cell
biology to discover that Drosophila iRhom regulates EGFR
signaling. The EGFR pathway inDrosophila has become amodel
for understanding how signaling pathways are regulated with
the precision that is necessary to control their multiple develop-
mental and physiological roles (Shilo, 2003). Drosophila iRhom
is expressed predominantly in neuronal cells, and its loss
causes a ‘‘sleep’’-like phenotype that is indistinguishable from
gain-of-EGFR signaling in the central nervous system. Consis-
tent with this, genetic interactions show that Drosophila iRhom
counteracts the function of active rhomboids, specifically acting
to inhibit EGFR signaling. As well as revealing the biological
role of Drosophila iRhom, we have investigated the cellularCell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc. 79
mechanism of iRhom function. Both fly and mammalian
iRhoms, which are localized in the ER, inhibit secretion and
intracellular levels of specific client proteins by promoting pro-
teasomal degradation. Overall, these data imply that iRhoms
regulate secretion of specific client proteins, which include the
EGF family of growth factors. We show that they can target
clients for proteasomal removal by ER-associated degradation
(ERAD). In this way, fundamental cellular quality control
machinery is exploited as a mechanism for regulating growth
factor signaling.
RESULTS
iRhoms Lack Proteolytic Activity
Biochemical and structural analysis of rhomboid proteases
has identified the two essential catalytic residues as being
serine-201 and histidine-254 (numbered according to E. coli
GlpG) (Wang et al., 2006). Phylogenetic alignment of eukaryotic
rhomboid-like proteins identified a well-conserved subfamily in
which one or both of these catalytic residues were missing,
despite otherwise having clear sequence and topological
similarity to the active rhomboids (Figure 1A) (Lemberg and
Freeman, 2007). The human genes have been named Rhbdf1
and Rhbdf2, but the generic term iRhoms has been proposed
to distinguish them from the active proteases (Lemberg and
Freeman, 2007). The degree of conservation of these iRhoms,
which are only found in metazoans, suggests that they are
under evolutionary selective pressure, but as they are not pre-
dicted to be active proteases, their function is unclear. iRhoms
have three prominent distinctions from active rhomboids:
a much longer N-terminal cytoplasmic domain, a large and
extremely conserved loop domain (the iRhom homology
domain) between the first two transmembrane domains, and
an invariant proline residue that is N terminal to the expected
location of the catalytic serine (i.e., GPx replacing the GxS
rhomboid catalytic motif). The significance of the iRhom-
specific proline was investigated by generating variants of
active rhomboids in which the residue immediately before the
catalytic serine was mutated to proline. This mutation abolished
the enzymatic activity of Drosophila Rhomboid-1 and strongly
reduced mouse RHBDL-2 activity in a cell culture assay
(Figures 1B–1D). The proline mutation also virtually abolished
the in vitro activity of the purified bacterial rhomboid AarA
(Strisovsky et al., 2009), demonstrating that it directly disrupts
the enzyme (Figure 1E).
This prediction that iRhoms are themselves catalytically inert
was tested by analyzing Drosophila iRhom, human iRhom1
(Rhbdf1), and mouse iRhom2 (Rhbdf2) in a cell culture proteol-
ysis assay. No proteolytic activity was detected against the
Drosophila EGFR ligands Gurken or Spitz, nor against mouse
EGF (Figures 1B–1D), all substrates of multiple rhomboids
(Urban et al., 2002a, 2002b; Adrain et al., 2011). We have further
tested Drosophila and mammalian iRhoms against a variety of
other rhomboid substrates without detecting any proteolytic
activity (data not shown). Overall, these data support the idea
that iRhoms have no proteolytic activity and demonstrate that
their characteristic proline is sufficient to disrupt the rhomboid
active site.80 Cell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc.Drosophila iRhom Is Expressed in Neuronal Cells
and Is Located in the ER
Unlike most sequenced metazoans, Drosophila has only a single
iRhom, encoded by the rhomboid-5 gene. In situ hybridization
showed that rhomboid-5/iRhom RNA is expressed exclusively
in the central nervous system of embryos: transcripts are
strongly detected in the ventral nerve cord and brain (Figure 2A).
In the third instar larva, rhomboid-5/iRhom expression was also
largely restricted to neural tissue: specifically behind the
morphogenetic furrow in the developing eye (Figure 2B), where
the adult retina develops, and in the embryonic brain, with
elevated levels in the optic lobes (Figure 2C). In adults, too,
iRhom RNA is highly enriched in the nervous system and brain
(http://www.flyatlas.org).
Individual active rhomboid proteases have specific locations
in the Golgi apparatus and plasma membrane (Figure 2D) or in
mitochondria (Lee et al., 2001; Urban et al., 2002a; McQuibban
et al., 2003). We used COS7 cells to determine the localization
of HA-tagged Drosophila iRhom, human iRhom1, and mouse
iRhom2. All were located specifically in the endoplasmic retic-
ulum (ER), as demonstrated by characteristic perinuclear and
reticular staining and by colocalization with the ER marker
protein disulphide isomerase (PDI) (Figure 2D). This is supported
by an earlier observation that human iRhom1 is located in the ER
in HNSCC 1483 cancer cells (Zou et al., 2009).
Drosophila iRhom Mutants Phenocopy Neuronal
EGFR Activation
To investigate iRhom function, we used homologous recombina-
tion to generate a null mutant of Drosophila iRhom (Figure S1
available online). None of the three mutant lines that we isolated
had discernible developmental defects. Homozygous mutations
did, however, cause a severe decrease in the daytime activity
pattern of adult flies compared to wild-type or heterozygous
controls (Figure 3A and Movie S1). The specificity of this
phenotype was confirmed by transheterozygotes between the
targeted mutation and a pre-existing deletion for the region
having the same phenotype (Figure 3A). Furthermore, UAS-
iRhom expressed under the control of the neuron-specific
ELAV-Gal4 driver fully rescued the activity of the mutant flies
(Figure 3B), whereas expression in muscle cells, under the
control of how24B-Gal4, did not. This confirms the specificity
of the phenotype and demonstrates that iRhom is required
specifically in neurons, a result that is consistent with the
nervous system-restricted expression pattern (Figures 2A–2C).
During the day, iRhommutant flies sometimes do not move for
periods of 1 hr, which is highly unusual. Prolonged periods of
inactivity could, in principle, be caused by increased resting
(a sleep-like state) or an impaired ability to move. To distinguish
these two possibilities, we measured the activity of flies during
periods of wakefulness. During their relatively few active periods
(147 over the course of the experiment, compared to 820 in the
control), mutants showed no reduction of movement; in fact, in
those periods, they moved slightly more than wild-type or
heterozygous controls (Figure 3C). To confirm this, we analyzed
video recordings and found mutants and wild-type to have the
same walking speed (Figure 3D). This indicates that iRhom
mutant flies can move normally and implies that their overall
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Figure 1. iRhoms Are Inactive Members of the Rhomboid-like Family
(A) iRhoms are highly conserved and lack the catalytic serine and/or histidine (arrows) of active rhomboids. Distinctive iRhom elements are long N termini,
a conserved iRhom homology domain (IRHD, blue), and an invariant proline residue (red) before the catalytic serine. Protein names and identifiers are indicated.
Note that the gene for Drosophila iRhom (Swiss-Prot:Q76NQ1; Rhomboid-5) is ambiguously predicted (Lemberg and Freeman, 2007).
(B andC)Western blots assaying proteolytic activity in COS7 cells. Flag-taggedGurken and Star (Grk+S) (B) or Flag-Spitz and Star (Spi+S) (C) were cotransfected
with HA-tagged versions of Rhomboid-1 (R1), a catalytic serine-to-alanine mutant of Rhomboid-1 (SA), a mutant Rhomboid-1 with an iRhom-like proline (AP), or
Drosophila iRhom. Cleavage of substrate inside the cells (extract) and secreted into the supernatant (sup) was detectedwith anti-Flag antibody. Cell extracts were
also probed with anti-HA and anti-actin as controls for rhomboid expression and gel loading. Wild-type Rhomboid-1 cleaves and releases Spitz and Gurken; the
SA mutant, AP mutant, and iRhom show no activity. Once cleaved, Spitz is rapidly secreted, explaining the absence of a cleavage product in the cell extract
(Urban and Freeman, 2003).
(D) A similar experiment using mouse HA-tagged RHBDL2 (mR2) and myc-tagged mouse EGF. The alanine-to-proline mutation (AP) strongly reduced EGF
secretion, and neither human iRhom1 nor mouse iRhom2 showed any catalytic activity. Mammalian iRhoms have been reported to be proteolytically processed
(Nakagawa et al., 2005), explaining the multiple bands in cell extracts. This assay was done in the presence of 10 mM BB94 to inhibit metalloprotease shedding.
Throughout the paper, ‘‘M’’ represents a mock transfection control and ‘‘SA’’ represents a serine-to-alanine catalytic mutant.
(E) The iRhom-like proline mutation in the active site of a bacterial rhomboid protease abolishes its enzymatic activity. AarA (WT), its catalytic serine-to-alanine
mutant (S150A, SA), and iRhom-like mutant (A149P, AP) were overexpressed in E. coli and purified in the presence of detergent. The substrates TatA and LacY
TM2were in vitro translated and radiolabeled. Enzyme and substrates were incubated at 37 for 40min.Wild-type AarA concentrations were 280 nM for TatA and
560 nM for LacY TM2. Mutants were equimolar to the wild-type or 5-fold higher when indicated (53). Cleavage products (P) were separated from the substrates
(S) by SDS PAGE and detected by autoradiography.inactivity is due to an increase in periods of inactivity between
active episodes. Consistent with this, sleep, typically defined
as periods of inactivity greater than 5 min (Greenspan et al.,
2001), was significantly increased in iRhom mutants (Figure 3E).
This same inactivity phenotype is caused by activation of
EGFR signaling upon transient CNS expression of Rhomboid-1and Star (Foltenyi et al., 2007). This is significant because of
the well-established functional relationship between active
rhomboids and EGFR activation (Wasserman et al., 2000; Urban
et al., 2001). Our results are therefore consistent with loss of
Drosophila iRhom in the nervous system leading to activation
of EGFR signaling, thereby decreasing daytime activity. ThisCell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc. 81
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Figure 2. Expression and Cellular Location of iRhoms
(A–C) RNA in situ hybridization of wild-type and iRhom mutant Drosophila
embryos, third-instar eye discs, and larval brains with a probe against
iRhom.
(A) iRhom is expressed in the embryonic CNS, including the ventral nerve cord
and brain.
(B) Third-instar larval eye discs showed staining posterior to the morphoge-
netic furrow (MF).
82 Cell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc.would imply that, under wild-type conditions, iRhom promotes
wakefulness by inhibiting EGFR activity.
Drosophila iRhom Is a Specific Inhibitor
of EGFR Signaling
The cellular mechanism by which EGFR signaling in the CNS
regulates Drosophila sleep patterns is not yet understood, so
to investigate further the genetic relationship between iRhoms
and EGFR, we used the well-characterized systems of imaginal
disc development. We looked for genetic interactions to test
the hypothesis that iRhoms act as physiological inhibitors of
EGFR activity. Halving the dose of iRhom, which alone caused
no phenotype, strongly enhanced the rough eye caused by
EGFR hyperactivity induced by Rhomboid-1 overexpression
(Figure 4A). Conversely, removal of iRhom suppressed the eye
phenotype caused by reduction of EGFR signaling, for example
when Argos, Sprouty, or a dominant-negative form of the EGFR
was overexpressed in the eye (Figure 4B). Both of these syner-
gistic interactions imply that iRhom inhibits EGFR signaling;
this was directly demonstrated by iRhom overexpression (using
GMR-Gal4) suppressing the rough eye caused by the overex-
pression of active Rhomboid-1 (Figure 4C).
In another set of experiments, we examined the consequences
of iRhom heterozygosity in combination with reduction in the
known EGFR inhibitory molecules Sprouty and Argos. Removing
one copy of sprouty triggered amild extra wing vein phenotype in
6.4% of adult flies grown at 29C; this was enhanced to 74.5%
when the dose of argos was simultaneously halved (Figure 4D).
Similarly, halving iRhom strongly enhanced the sprouty heterozy-
gous wing phenotype: 62.5% of wings had mild, and 3.65%
had strong extra vein phenotypes (Figure 4D). The additive effect
of all threegeneswas further demonstrated in the triple-heterozy-
gote combination, wherein mild (+) and severe (++) extra vein
phenotypeswere further increased to 87.5%and10.3%, respec-
tively (Figure 4D). Together, all of these synergistic genetic inter-
actions indicate that iRhom acts in the same pathway as Argos
and Sprouty and is an inhibitor of EGFR signaling.
Importantly, we also tested whether other developmentally
significant signaling pathways were similarly perturbed by
changes in the dose of iRhom. In an extensive series of experi-
ments, we found no evidence for genetic interactions with Wg,
Notch, Hedgehog, or Dpp signaling (Table S1). Overall, we
conclude that Drosophila iRhom inhibits EGFR activity in vivo;
that this role is particularly prominent in the nervous system
but can be detected in the developing wing and eye under sensi-
tized conditions; and that, although we cannot rule out a role in
pathways that have not been tested, this effect is largely specific
to the EGFR-signaling pathway.(C) iRhom expression is detected at low levels throughout the larval brain and
is elevated in the optic lobes (arrowheads).
(D) HA-tagged Drosophila iRhom, human iRhom1, and mouse iRhom2 were
located in the endoplasmic reticulum (ER) in COS7 cells. Drosophila Rho-1
localized to the Golgi apparatus, and the mouse rhomboid RHBDL3 localized
to the Golgi apparatus, the plasma membrane, and punctate endosome-like
structures. HA antibodies were used to detect iRhom; antiprotein disulfide
isomerase (PDI) was an ERmarker; and anti-P230 was used as a Golgi marker.
See also Figure S1.
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Figure 3. Loss of iRhom Results in
Increased Sleep
(A and B) Activity levels over 2 days of male flies of
indicated genotypes plotted as activity counts per
hr (error bars represent mean ± SEM). Bars above
the diagrams indicate light (white) and dark (black)
periods of 12 hr each. Data represent measure-
ments from two to four independent experiments.
(A) Activity patterns of heterozygous (iRhomKO1/+;
n = 18), homozygous iRhommutant (iRhomKO1/KO1;
n = 16), and transheterozygotes (iRhomKO1/Df (2L)
J17; n = 17). iRhom homozygotes and trans-
heterozygotes between iRhomKO1 and Df(2L)J17
show highly suppressed activity levels.
(B) Neuronal expression of UAS-iRhom (n = 27),
but not UAS-RFP (n = 24), by ELAV-Gal4 rescues
the inactivity phenotype of iRhomKO1/KO1 (n = 16)
flies. Expression of iRhom in muscle under the
control of how24B-Gal4 (n = 38) does not rescue
the activity pattern.
(C) Waking activity, expressed as an average
number of beam crossings in each minute in
which activity was detected, was slightly
increased in iRhomKO1/KO1 (n = 17) flies compared
to iRhomKO1/+ (n = 16) and wild-type controls
(n = 21). In this and subsequent panels, signifi-
cance was determined with Student’s t test (ns,
not significant). Error bars represent mean ± SEM.
(D) The movement of wild-type (n = 5) and
iRhomKO1/KO1 (n = 5) flies was filmed. Fly move-
ment was tracked during an active period, and the
average walking speed (excluding short stops)
was calculated in arbitrary units. Error bars
represent mean ± SEM.
(E) Sleep, defined as periods of inactivity greater
to or equal than 5min, was significantly elevated in
iRhomKO1/KO1 flies (n = 39) compared to hetero-
zygous (iRhomKO1/+, n = 33) and wild-type (n = 44)
controls. Error bars represent mean ± SEM.
See also Movie S1.To confirm that disruption of the EGFR pathway also can
explain the sleep-like iRhom phenotype, we looked for similar
genetic interactions affecting activity (Figure 4E). Reduction of
EGFR signaling by RNAi knockdown of the EGF receptor itself,
or its activating ligand Spitz, significantly rescued the iRhom
loss-of-function phenotype, supporting the idea that the lethargy
in the mutant flies is indeed caused by excess EGFR activity
(Figure 4E).
Drosophila and Mammalian iRhoms Specifically Inhibit
Rhomboid-Triggered Ligand Release
The genetic data described above demonstrate a physiological
role for Drosophila iRhom but cannot provide direct mechanistic
insight. For this, we turned to cell culture, asking whether
iRhoms can interfere with the function of active rhomboid
proteases. When Gurken, a Drosophila EGF family ligand, and
Drosophila Rhomboid-1 are coexpressed in COS7 cells, Gurken
is cleaved and its extracellular domain is released into the
culture medium (Figure 5A) (unlike Spitz, Gurken does not
require the action of Star [Yogev et al., 2008]). Coexpression
of Drosophila iRhom inhibited the release of soluble Gurkeninduced by Rhomboid-1 (Figure 5A). This effect was specific,
to the extent that the release into the medium of two other
proteins, Delta, a transmembrane protein subject to metallopro-
tease shedding, and Wnt3A, a secreted protein, was unaffected
by iRhom expression (Figure 5B and Figure S2A). We also ruled
out a different kind of nonspecific effect by coexpressing with
Gurken and Rhomboid-1 similar levels of an unrelated polytopic
ER protein, Unc93B (Brinkmann et al., 2007). This caused no
reduction of Gurken release (Figure 5C), implying that the iRhom
effect was not a nonspecific consequence of overexpressing
a polytopic membrane protein (for example, caused by overload
of the ER). We also found that the release of Spitz, another
Drosophila EGFR ligand, is similarly blocked by iRhom coex-
pression (data not shown). Together, these results show that
Drosophila iRhom specifically inhibits EGFR ligand release
from cells. Because iRhoms are conserved in all metazoans,
we asked whether their function might be conserved between
Drosophila and mammals. When human iRhom1 (data not
shown) or mouse iRhom2 were coexpressed with mouse EGF
and the mouse active rhomboid, RHBDL2 (Adrain et al., 2011),
secretion of soluble EGF was inhibited (Figure 5D), implyingCell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc. 83
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Figure 4. Drosophila iRhom Inhibits EGFR Signaling
(A) The rough eye caused by sevenless-driven Rhomboid-1 overexpression (sev-rho-1/+) is strongly enhanced by halving the dose of iRhom (iRhomKO1/+;
sev-rho-1/+).
(B) Loss of iRhom suppressed the rough eyes caused by reduction of EGFR signaling mediated by UAS-driven: dominant negative Egfr (U-DN-Egfr); argos
(U-argos); and sprouty (U-sty). The driver in all cases was the eye-specific GMR-Gal4.
(C) Expression of UAS-iRhom under the control ofGMR-Gal4 suppressed the rough eye caused by sev-rhomboid-1 expression. This was particularly obvious at
the anterior edge of the eye indicated by white arrowheads.
(D) Genetic interactions in the wing. Examples of wing phenotypes and severity levels indicated by wild-type (WT), mild (+), and severe (++) are shown. Wings of
flies that were heterozygous for argos (argoslD7/+) or iRhom (iRhomKO1/+) were wild-type; 6.4% (± 6.4%) of wings that were heterozygous for sprouty (styS73/+)
showedmild extra vein phenotypes (black arrowheads), typical of slight EGFR hyperactivation. A transheterozygous combination of styS73 and argoslD7 enhanced
the extra vein phenotype (74.5% ± 6.4% with mild extra veins). Similarly, halving iRhom in combination with styS73 (iRhomKO1/+; styS73/+) enhanced the
phenotype (62.5% ± 11.6%mild; 3.65% ± 5.4% severe). iRhomKO1/+; styS73/ argoslD7 flies showed a further increase in penetrance and strength of the extra vein
phenotype (87.5% ± 2.3%mild; 10.3% ± 3.8% severe). All flies for this experiment were grown at 29C. Error bars represent standard deviations of three to four
independent experiments (n = 50 per experiment).
(E) iRhomKO1/KO1 flies (n = 44) showed increased daytime sleep compared to controls (elav-GAL4, n = 37). Inhibition of EGFR signaling in the nervous system by
expression of RNAi constructs against spitz (elav-GAL4; iRhomKO1/KO1; UAS-spiRNAi, n = 27) and Egfr (elav-GAL4; iRhomKO1/KO1; UAS-EgfrRNAi, n = 36) signif-
icantly (p < 0.0001) suppressed the iRhomKO1/KO1 sleep phenotype. Error bars represent mean ± SEM.
See also Table S1.
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Figure 5. iRhom Inhibits Secretion of EGF Family Ligands
(A–C) COS7 cell supernatants (sup) were analyzed for Grk secretion, and cell extracts were blotted for levels of HA-tagged iRhom and Unc93B (Brinkmann et al.,
2007). The ratios of iRhom to Drosophila Rhomboid-1 (R1) indicate relative amounts of transfected DNA.
(A) Rhomboid-1 (R1)-induced secretion of Flag-Grk was inhibited by increasing amounts of iRhom.
(B) Secretion of the FLAG-tagged Delta was unaffected by increasing amounts of iRhom.
(C) Overexpression of the ER resident polytopic membrane protein Unc93B did not interfere with Grk secretion.
(D) Mouse iRhom2 (iR2) inhibited mouse RHBDL2 (R2)-induced secretion of EGF. Secreted mouse EGF was detected by anti-EGF. The metalloprotease
inhibitor BB94 suppressed nonspecific shedding of EGF. Increasing amounts of HA-tagged mouse iRhom2 (bottom) inhibited RHBDL2-mediated EGF
secretion (top).
(E and F) Drosophila iRhom destabilizes intracellular Gurken. Rhomboid-1-mediated Grk processing was inhibited by iRhom (E), but not Unc93B (F). Histograms
show relative substrate (S) to product (P) conversion from the western blots above. The iRhom-to-Rho1 (iRhom:R1) and Unc93B:R1 ratios indicate relative
amounts of transfected DNA. Equal loading was confirmed by probing cell extracts for actin levels. Error bars represent mean ± SD.
(G) The iRhom effect was rescued by expression of ER-localized, but not Golgi-localized, active rhomboid. KDEL-tagged Rhomboid-1 (R1-KDEL), but not
the inactive serine-to-alanine mutant Rhomboid-1 (Rho1 SA-KDEL), induced secretion of Grk in supernatants. A constant amount of iRhom inhibited Grk
secretion (83 more iRhom DNA transfected than R1-KDEL). Increasing amounts of HA-tagged R1-KDEL rescued Grk secretion. Using the same approach,
untagged Rhomboid-1, which is Golgi localized (see Figure 2D), did not rescue Grk secretion (right). HA-tagged iRhom, R1-KDEL, and R1 were detected in cell
extracts. Flag-tagged Grk was detected in the supernatants (top) and extracts (middle). The Grk substrate band was absent when R1-KDEL is used because of
efficient processing when substrate and enzyme are both in the ER.
See also Figure S2.that both mammalian iRhoms had a similar function to their
Drosophila counterpart.
iRhoms Specifically Reduce Intracellular Levels of EGF
Family Ligands
The specific inhibitory effect of iRhom on the accumulation of
soluble Gurken in the cell culture medium was also reflected in
cell extracts, but in this case, we detected two distinct effects.
First, iRhom coexpression reduced Gurken cleavage by Rhom-
boid-1, expressed as relative substrate conversion (Figure 5E).
Second, the total level of intracellular Gurken, intact and cleaved,was reduced by iRhom coexpression (Figure 5E). Again, controls
imply that this was a specific effect: the polytopic ER protein
Unc93B did not reduce Gurken cleavage or intracellular levels
(Figure 5F), and neither Wnt3A nor Delta were destabilized by
iRhom expression (Figures S2B and S2C). Finally, all of these
effects were efficiently rescued by the additional expression of
an ER-targeted version of Rhomboid-1, but only slightly rescued
by high levels of wild-type Rhomboid-1, which is located in the
Golgi apparatus (Figure 5G). This result is important for a number
of reasons. First, it further demonstrates that the iRhom effect is
not caused by a nonspecific disruption of the secretory pathway.Cell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc. 85
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Figure 6. iRhoms Induce Degradation of EGFR Ligands Indepen-
dently of Active Rhomboids
(A and B) Secretion and intracellular levels of the indicated EGFR ligands were
decreased by human iRhom1 (iR1-HA) and mouse iRhom2 (iR2-HA) but
unaffected by mouse Unc93B.
(C) Secretion and intracellular levels of Flag-tagged Delta were unaffected by
iR1, iR2, and Unc93B. EGFR ligands and Delta were detected with myc and
Flag antibodies, respectively. The effects of mammalian iRhoms and Unc93B
on intracellular levels of EGF, TGFa, and Delta were quantified from three
independent experiments and plotted as relative percentages (error bars
86 Cell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc.Second, once Gurken has been solubilized by an active rhom-
boid, it is no longer subject to iRhom-mediated destabilization.
Third, the fact that ER-restricted Rhomboid-1 rescues much
more efficiently than Golgi-localized Rhomboid-1 argues that
iRhom function occurs in the ER, not later in the secretory
pathway. The slight rescue by wild-type Rhomboid-1 presum-
ably reflects the low steady-state level in the ER as it is trafficked
to the Golgi apparatus.
iRhom Acts in Absence of Active Rhomboid
Two classes of mechanism could explain our data: the iRhoms
might either inhibit the function of active rhomboid proteases,
for example by a dominant-negative effect, or could act directly
on substrates, destabilizing them and preventing them from
being cleaved by proteases. We took advantage of the absence
of endogenous rhomboid activity in COS7 cells (Urban and
Freeman, 2003; Adrain et al., 2011) to distinguish these models
by testing the effect of iRhom in the absence of an active rhom-
boid. Human iRhom1 or mouse iRhom2 were coexpressed with
EGF and other EGF family ligands. Under these conditions,
ligand release was dependent on ADAM family metallopro-
teases, which were not chemically inhibited (as they were in
some previous experiments). Strikingly, the secretion and intra-
cellular levels of all EGFR ligands tested (EGF, TGFa, Epiregulin
[EPR], Amphiregulin [AREG], Betacellulin [BTC], andNeuregulin 4
[Nrg4]) were downregulated by the expression of either
iRhom (Figures 6A and 6B and Figures S3A–S3D). Two control
proteins, prolactin, a constitutively secreted protein, and Delta, a
membrane protein that is subject to metalloprotease shedding,
but not cleaved by rhomboids, were unaffected by iRhom
expression (Figure 6C and Figure S3E). As before, specificity
was demonstrated by showing that Unc93B did not cause the
same effect (Figures 6A–6C and Figures S3A–S3D). By repeating
the experiment in HeLa cells, we also confirmed that the specific
downregulation of EGF by iRhoms was not limited to COS cells
(Figure S3F). These experiments clearly demonstrate that
iRhoms can downregulate mammalian EGF family ligands (not
all of which are rhomboid substrates [Adrain et al., 2011]) in the
absence of any active rhomboid, thereby strongly supporting
a model whereby iRhoms act directly on EGFR ligands (or
possibly other clients), rather than by inhibiting the rhomboid
enzymes themselves.
We further tested this model by examining whether a mutant
version of EGF (A1031F) that cannot be cleaved by rhomboids
but is susceptible to ADAM release (Adrain et al., 2011) was
sensitive to iRhom coexpression. Both human iRhom1 and
mouse iRhom2 downregulated EGFA1031F and inhibited its
release into the medium of COS7 cells (Figure 6D). This furtherindicate standard deviations). Levels of iRhom1, iRhom2, and Unc93B were
monitored by anti-HA antibodies in the cell extracts. In all panels, blots were
probed with anti-actin to control for equal loading.
(D) HA-tagged human iRhom1 and mouse iRhom2, but not Unc93B, reduced
secretion and intracellular levels of Flag-EGF-A1031F.
(E) iRhom1 and iRhom2 destabilize myc-EGF levels in cell extracts, but
a KDEL-tagged (and therefore ER-localized) catalytically inactive mutant of
mouse RHBDL2 (HA-R2SA-KDEL) has no effect.
See also Figure S3.
confirms that iRhoms can act on proteins that are not themselves
substrates of rhomboid proteases.
Is the iRhom effect simply a consequence of an interaction
between a catalytically dead rhomboid and a potential
substrate? We tested this by investigating whether catalytic
mutants of mouse RHBDL2 would mimic the iRhom effect on
EGF. No downregulation of EGF was detected upon expression
of an ER-targeted mutant of RHBDL2 (Figure 6E).
In summary, these experiments lead us to conclude that
Drosophila and mammalian iRhoms share a conserved function;
that iRhoms inhibit rhomboid-catalyzed release of growth
factors by acting on the potential rhomboid substrates, rather
than by inhibiting the enzymes themselves; and that the iRhoms
have a specific function beyond just being catalytically inactive
rhomboid proteases. An important further conclusion is that,
although iRhoms show significant specificity, they can act on
proteins that are not direct rhomboid substrates.
iRhoms Trigger Proteasomal Degradation
of Rhomboid Substrates
The observed reduction of EGF family ligands induced by
iRhoms suggested that they might be degraded in the cell.
We therefore asked whether inhibition of the proteasome
would suppress iRhom-induced downregulation. Myc-tagged
mouse EGF was coexpressed with iRhom1 in the presence
or absence of proteasomal inhibitors. As expected, iRhom
expression caused a substantial reduction of EGF, both in cell
extracts and secreted into the culture medium. This reduction
was completely rescued by treatment with MG132, implying
that the destabilization of EGF depended on proteasomal
activity (Figure 7A). This result was confirmed with another pro-
teasome inhibitor, lactacystin (Figure S4A). We also used
qPCR to show that the observed increases in EGF levels were
not caused by nonspecific transcriptional effects of the protea-
some inhibitors (Figures S4B and S4C). Because EGF resides
in the secretory pathway, it is not directly accessible to protea-
somes in the cytoplasm. However, proteins can be extracted
from the ER for proteasomal destruction in a process called
ER-associated degradation (ERAD) (Brodsky and Wojcikiewicz,
2009). The location of iRhoms in the ER is consistent with
a potential role in promoting ERAD. Interestingly, even in the
absence of iRhom, MG132 treatment also slightly increased
the steady-state level of intracellular EGF (Figure 7A), implying
that, even under normal conditions, some EGF is degraded by
the proteasome.
The conclusion that iRhom drives EGF into the ERAD
machinery suggests that the two proteins might directly interact
in the ER. Indeed, Flag-tagged EGF was specifically coimmuno-
precipitated by HA-tagged human iRhom1 and mouse iRhom2,
whereas control proteins, TGN36 and prolactin, were not
(Figure 7B).
To monitor the kinetics of intracellular EGF, which can leave
the cell by secretion or be degraded by the proteasome, we per-
formed a pulse-chase experiment (Figure 7C). Because iRhom is
expressed before the label is added, the iRhom effect is already
apparent at the earliest stage of the chase, complicating the
interpretation of this experiment. Nevertheless, this kinetic anal-
ysis is fully consistent with the steady-state data (Figure 7A andFigure S4A). In untreated cells, a pulse of labeled EGF (Figure 7C,
blue diamonds) disappears from cells during a 3 hr time course.
As expected, coexpression of iRhom1 reduces the level of EGF
(Figure 7C, green triangles); again, all EGF disappears during
the 3 hr chase. Addition of MG132 to inhibit the proteasome
increases the initial level of EGF, confirming that ERAD contrib-
utes to EGF homeostasis (Figure 7A), but most of the EGF is still
secreted by the cell over 3 hr (Figure 7C, red squares). Interest-
ingly, coexpression of iRhom in cells in which the proteasome is
inhibited (Figure 7C, purple crosses) slows down EGF secretion.
This partial ER-anchoring effect by iRhom when it cannot
promote ERAD is consistent with its direct binding to EGF
(Figure 7B).
Finally, the in vivo relevance of this model was tested by using
Drosophila genetics to look for evidence that ERAD contributes
to the normal regulation of EGFR signaling. Inhibition of EGFR
signaling by overexpression of either Sprouty or Argos was sup-
pressed by RNAi knockdown of the ERAD factors Hrd1 (Fig-
ure 7D) or EDEM2 (Figure S4D). This implies that ERAD does
indeed regulate EGFR signaling in the Drosophila eye. Overall,
these data suggest that EGF levels in Drosophila and perhaps
in mammals are normally kept in balance by low-level ERAD
and that iRhoms exploit this mechanism to regulate growth
factor signaling (Figure 7E).
DISCUSSION
We report that iRhoms, which evolved from active rhomboids,
act in Drosophila as negative regulators of rhomboid-dependent
proteolysis, thereby inhibiting EGF receptor signaling in the
nervous system. iRhom mutants have activity defects that are
consistent with a role for EGFR signaling in controlling sleep in
flies. We have shown that iRhom function, binding to EGF family
ligands in the ER and allowing them to be targeted for degrada-
tion by ERAD, is shared between Drosophila and mammals.
These results provide an unexpected and conserved mecha-
nistic link between the cellular quality control machinery and
the regulation of growth factor signaling.
ERQuality Control and theRegulation of Intramembrane
Proteolysis
Intramembrane proteases are potentially dangerous enzymes:
they catalyze the irreversible cleavage of proteins that trigger
important cellular processes. Their regulation is therefore para-
mount, but little is known about how this is achieved under
physiological conditions. Nevertheless, several lines of evidence
suggest that intramembrane proteases rely heavily on regulated
segregation of substrate and enzyme (Freeman, 2008). For
example, in Drosophila, the type II membrane protein Star regu-
lates access of substrates to rhomboids (Lee et al., 2001; Urban
et al., 2001). Similarly, the trafficking of the site-2 protease
substrates SREBP or ATF6 to the Golgi apparatus, the location
of S2P, is highly regulated (Sakai and Rawson, 2001; Shen
et al., 2002). Here, we report a new mechanism, the specific
destabilization of substrates in the ER, ultimately preventing
access to an active rhomboid. Our point is not that these diverse
control strategies share common mechanisms, but that they all
comply with the regulatory logic of segregating substrate andCell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc. 87
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Figure 7. iRhoms Destabilize EGFR Ligands by ERAD
(A) Secretion and intracellular protein levels of myc-EGF were increased upon MG132 treatment at 10 mM for 12 hr (compare DMSO-treated lane 1 with MG132-
treated lane 2 in supernatant and extracts). The inhibition of myc-EGF secretion and intracellular myc-EGF levels caused by human iRhom1-HA coexpression
(compare lane 1 with lane 3) was rescued by MG132. The histogram quantifies the data: intracellular stabilization was expressed as the ratio of band intensity of
MG132 treatment divided by DMSO control. MG132 stabilized steady-state levels of myc-EGF 3.4- ± 1.7-fold in the absence of coexpressed iRhom1 and 28.5- ±
15.2-fold in the presence of iRhom1. Error bars represent mean ± SD.
(B) EGF coimmunoprecipitates with both iRhom1 and iRhom2. The proteins were coexpressed in HEK293 cells as indicated. Two control proteins, TGN36 and
prolactin (PRL), showed no interaction with either iRhom. The levels of each protein in the cell lysates are shown in the middle and bottom panels.
(C) A 10 min pulse of 35S-methionine/cysteine was used to label Flag-tagged EGF, and its kinetics were followed for 3 hr ±MG132 and ± human iRhom1 (iR1). An
autoradiogram of immunoprecipitated Flag-EGF (arrowhead) showed that iRhom1 reduced EGF levels at all chase time points (compare lanes 1/2, 5/6, and 9/10).
MG132 increased EGF levels (compare lanes 1/3, 5/7, and 9/11) and rescued iRhom1-induced EGF destabilization (compare lanes 2/4, 6/8, and 10/12). The star
indicates an unspecific degradation product. Quantification of the autoradiogram showed that, when the proteasome is inhibited, iRhom1 reduced the rate of
secretion of EGF (compare slopes of red and purple lines).
(D) Expression of EGFR inhibitors Sprouty (GMR/+; U-sty/U-GFP) or Argos (GMR/+; U-argos/U-GFP) caused a rough eye. Reduction of ERAD by RNAi
knockdown of Hrd1 (GMR/+; U-hrd1RNAi) suppressed this EGFR inhibition.
(E) Model of iRhom function. EGF (in green) secretion is homeostatically regulated by ERAD; iRhoms (in red) bind to EGF, holding it in the ER and thereby
enhancing ERAD and inhibiting secretion.
See also Figure S4.enzyme. This contrasts with the regulation of soluble proteases,
in which there is greater emphasis on regulating enzyme activity.
This distinction reflects the greater ability to restrict and control
the cellular location of membrane proteins than soluble proteins.
ERAD was first discovered as a mechanism for removing
misfolded components of the T cell receptor complex (Lippin-
cott-Schwartz et al., 1988). It is now clear that it contributes
more generally to ER quality control and homeostasis (Brodsky
and Wojcikiewicz, 2009). Our data extend the biological conse-88 Cell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc.quences of ERAD by demonstrating that it has been recruited
in metazoans as a way of regulating intercellular signaling.
Although many ERAD components have been identified, the
molecular details of how proteins are targeted for recognition
and retrotranslocation remain unclear (Brodsky and Wojcikie-
wicz, 2009). iRhoms are polytopic ER membrane proteins that
can bind to at least two rhomboid substrates (this work and
Nakagawa et al., 2005). They could enhance ERAD actively
by introducing clients into the retrotranslocation machinery or
passively by prolonging ER retention, thereby increasing the
probability of exposure to ERAD. We do not know how many
proteins iRhoms affect; our genetic and cell biological data
show significant specificity, but the fact that mammalian
iRhoms target EGF ligands that are not rhomboid substrates
(see Figure 6 and Figure S4) implies that they have evolved addi-
tional clients.
Regulation of Drosophila EGF Receptor Signaling
Our data also demonstrate the physiological significance of
iRhoms in Drosophila: they are specific regulators of EGFR
signaling. In mammals, our data also show that iRhoms can
inhibit secretion of EGF family ligands, but in contrast to flies,
the physiological significance is not yet clear. The Drosophila
EGF receptor is probably the most genetically well-character-
ized growth factor receptor in any system (Shilo, 2003), and it
is striking how many distinct proteins contribute to its control.
Our experiments demonstrate that iRhom is a new type of
regulator of EGFR activity—the most upstream control element
in the pathway yet discovered. A theme that has emerged is
the importance of negative feedback as a way of limiting the
extent and/or amplitude of signaling (Freeman, 2000). The fact
that iRhom is transcriptionally activated in the developing eye
imaginal disc (Figure 2B) in cells with active EGFR signaling
implies that, at least in that context, iRhom could also participate
in a feedback loop. Intriguingly, its expression pattern shows
that, in the eye at least, its expression peaks at a time when
EGFR signaling needs to be switched off (Freeman, 1996).
Degradation of EGFR ligands could therefore represent a robust
way of preventing inappropriate EGFR signaling.
Although we can detect the role of iRhom in the development
of the wing and eye under genetically sensitized conditions, the
only prominent phenotype caused by loss ofDrosophila iRhom is
behavioral. This is consistent with its expression pattern, which
is largely restricted to the nervous system. An important open
question is whether the activity phenotype of iRhom mutant flies
is a consequence of a developmental or physiological defect.
Loss of iRhom causes flies to undergo excessive periods of inac-
tivity during the daytime, when wild-type flies are active. In fact,
iRhom mutants appear to be the first loss-of-function mutations
to have an excess sleep-like phenotype (Cirelli and Bushey,
2008). Drosophila has become a genetic model to investigate
the neuronal and molecular mechanisms of sleep (Greenspan
et al., 2001), and our data support the recent report that abnor-
mally high EGFR activity in the CNS leads to inactivity in flies
(Foltenyi et al., 2007).
Evolutionary Significance of iRhoms
The iRhoms have evolved from rhomboid proteases that lost
their catalytic activity but retained their location in the secretory
pathway and the ability to bind their substrates. This allowed
them to acquire new functions as specific regulators of secreted
proteins, without retaining a direct mechanistic interaction with
the proteases. Because many mutations will lead to loss of cata-
lytic activity, the evolution of regulatory proteins from ‘‘dead’’
enzymes might be quite common. The expression pattern,
cellular location, and substrate binding capacity of such proteins
provide an ideal platform for the subsequent acquisition ofspecific regulatory properties. Consistent with this idea is the
striking existence of inactive cognates of most proteases—
indeed of many enzymes of all families (Pils and Schultz, 2004;
Rawlings et al., 2010). Little or nothing is known about most of
these pseudoenzymes, the widespread existence of which has
only become apparent as genomes have been extensively
sequenced. But we find it an attractive idea that many will
have regulatory functions related to the enzymes from which
they evolved.
EXPERIMENTAL PROCEDURES
Drosophila Strains and Genetics
All crosses were performed at 25C unless otherwise stated. Fly strains are
described in the Supplemental Information.
Generation of iRhom Knockout Flies
The iRhomKO1/KO1 flies were generated by ends-out homologous recombina-
tion (Gong and Golic, 2003). The procedure is described in the Supplemental
Information.
In Situ Hybridization
The 2.4 kb iRhom coding sequence was cloned into pENTR/SD/D-TOPO
vector (Invitrogen) using directional TOPO cloning according to manufac-
turer’s instructions. DIG-labeled RNA (Roche) antisense probes were tran-
scribed using the T7 promoter. In situ hybridization on imaginal discs and
embryos were carried out using standard procedures (Cubas et al., 1991).
Scanning Electron Microscopy of Adult Eyes
Flies were frozen for at least 1 hr at 80C, mounted onto aluminum electron
microscope specimen stubs, and coated with 20 nm of a gold-palladium
mixture. Samples were viewed on a Philips XL30 scanning electron
microscope.
Cloning and Point Mutagenesis
Plasmids were generated according to standard cloning techniques, and their
detailed description is given in the Supplemental Information.
Protein Expression, Purification, and Rhomboid In Vitro Assays
Providencial stuartii rhomboid AarA was expressed in E. coli and purified
according to published protocols (Stevenson et al., 2007). In vitro activity
assays were carried out as described (Strisovsky et al., 2009).
Immunofluorescence
COS7 cells were stained as described in Lee et al. (2001), and imaging was
performed using a Zeiss 710 Confocal Microscope. Primary antibodies were
mouse monoclonal anti-HA 16B12 (1:100, Covance), mouse monoclonal
anti-P230 (1:100, BD Bioscience), and polyclonal anti-PDI (1:250, Calbio-
chem). Alexa Fluor 568 (red)- and Alexa Fluor 488 (green)-conjugated
secondary antibodies from Molecular Probes were used at 1:500.
Cell Culture-Based Assays
Cells were grown under standard conditions. Assay methods and antibody
details are described in the Supplemental Information.
Quantitative RT-PCR Measurements of EGF mRNA Levels
Assay methods and reagents are described in the Supplemental Information.
Activity Data Collection, Fly Tracking, Velocity Calculations,
and Statistical Analysis
Locomotor activity was monitored using the DAMS/Trikinetics system (Joiner
et al., 2006), and sleep was measured in 5 min bins as previously described
(Shaw et al., 2000).Waking activity (counts perminute) was calculated by aver-
aging activity counts for every active 1 min period (Andretic and Shaw, 2005).
All flieswere kept on a 12 hr light/dark cycle at 25C. Individual flies were filmedCell 145, 79–91, April 1, 2011 ª2011 Elsevier Inc. 89
with a video camera at 25 frames per second. Flies were tracked manually
using the ImageJ plug-in Manual Tracking (http://rsb.info.nih.gov/ij/plugins/
index.html).
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